Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
Why Are BioXcel Therapeutics Shares Down Friday?
10:27am, Friday, 06'th Mar 2026
BioXcel Therapeutics Inc. (NASDAQ: BTAI) shares are down on Friday.
BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study support potential future development of BXC
BioXcel Therapeutics, Inc. (BTAI) Discusses Phase III Results and Advances in Treating Acute Agitation in Alzheimer's Dementia Transcript
Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer's dementia Large patient population affected by Alzhei
Short Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Increases By 32.6%
04:35am, Wednesday, 04'th Feb 2026
BioXcel Therapeutics, Inc. (NASDAQ: BTAI - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 1,365,977 shares,
sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI ® Submission timeline supports potential a
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
12:44pm, Thursday, 15'th Jan 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting
07:00am, Monday, 12'th Jan 2026
Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Sett
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
07:00am, Wednesday, 07'th Jan 2026
NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicin
BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript
06:42am, Thursday, 11'th Dec 2025
BioXcel Therapeutics, Inc. (BTAI) Discussion of Managing Acute Agitation in Schizophrenia and Bipolar Disorders at Home Transcript
Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs.
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
09:26am, Wednesday, 12'th Nov 2025
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.18 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to a loss of $5.12 per share a year ago.
NEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
11:38am, Friday, 24'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
07:00am, Tuesday, 14'th Oct 2025
NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur
